Olema Pharmaceuticals, Inc. Financials
This page shows Olema Pharmaceuticals, Inc. (OLMA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Olema Pharmaceuticals, Inc. passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
For every $1 of reported earnings, Olema Pharmaceuticals, Inc. generates $0.90 in operating cash flow (-$146.7M OCF vs -$162.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Olema Pharmaceuticals, Inc.'s EBITDA was -$178.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 25.6% from the prior year.
Olema Pharmaceuticals, Inc. reported -$162.5M in net income in fiscal year 2025. This represents a decrease of 25.5% from the prior year.
Olema Pharmaceuticals, Inc. earned $-1.87 per diluted share (EPS) in fiscal year 2025. This represents an increase of 15.0% from the prior year.
Cash & Balance Sheet
Olema Pharmaceuticals, Inc. held $48.3M in cash against $0 in long-term debt as of fiscal year 2025.
Olema Pharmaceuticals, Inc. had 81M shares outstanding in fiscal year 2025. This represents an increase of 9.5% from the prior year.
Margins & Returns
Olema Pharmaceuticals, Inc.'s ROE was -34.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 2.3 percentage points from the prior year.
Capital Allocation
Olema Pharmaceuticals, Inc. invested $157.7M in research and development in fiscal year 2025. This represents an increase of 26.6% from the prior year.
OLMA Income Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | $40.0M-9.0% | $43.9M+43.4% | $30.6M | N/A | $33.2M+14.1% | $29.1M-2.6% | $29.9M |
| SG&A Expenses | N/A | $5.9M+49.6% | $4.0M-6.8% | $4.2M | N/A | $4.4M-0.6% | $4.4M-0.8% | $4.5M |
| Operating Income | N/A | -$45.9M+4.2% | -$47.9M-37.3% | -$34.9M | N/A | -$37.6M-12.2% | -$33.5M+2.4% | -$34.3M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | N/A | -$42.2M+3.6% | -$43.8M-44.1% | -$30.4M | N/A | -$34.6M-13.7% | -$30.4M+1.9% | -$31.0M |
| EPS (Diluted) | N/A | $-0.49+3.9% | $-0.51-41.7% | $-0.36 | N/A | $-0.60-11.1% | $-0.54+3.6% | $-0.56 |
OLMA Balance Sheet
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $533.4M+51.3% | $352.5M-7.7% | $382.0M-6.7% | $409.6M-9.2% | $451.0M+95.9% | $230.2M-9.6% | $254.6M-3.5% | $263.7M |
| Current Assets | $515.5M+54.2% | $334.3M-9.1% | $367.7M-7.3% | $396.7M-9.5% | $438.5M+101.1% | $218.0M-10.0% | $242.2M-3.9% | $252.1M |
| Cash & Equivalents | $48.3M+37.0% | $35.3M-32.8% | $52.5M+3.6% | $50.6M-63.7% | $139.5M+288.7% | $35.9M+112.5% | $16.9M-49.9% | $33.7M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $54.9M+22.0% | $45.0M+22.3% | $36.8M+40.4% | $26.2M-37.7% | $42.0M+34.4% | $31.3M+14.1% | $27.4M+0.1% | $27.4M |
| Current Liabilities | $51.8M+24.4% | $41.7M+25.6% | $33.2M+27.2% | $26.1M-37.6% | $41.8M+36.0% | $30.7M+15.7% | $26.5M+1.2% | $26.2M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $478.6M+55.6% | $307.5M-10.9% | $345.2M-10.0% | $383.5M-6.2% | $409.0M+105.6% | $198.9M-12.4% | $227.2M-3.9% | $236.3M |
| Retained Earnings | -$597.6M-8.4% | -$551.5M-8.3% | -$509.3M-9.4% | -$465.5M-7.0% | -$435.1M-8.4% | -$401.5M-9.4% | -$367.0M-9.0% | -$336.6M |
OLMA Cash Flow Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$38.3M-11.0% | -$34.5M-15.5% | -$29.9M+32.1% | -$44.0M-67.3% | -$26.3M+2.7% | -$27.0M+2.0% | -$27.6M-17.3% | -$23.5M |
| Capital Expenditures | N/A | $0 | N/A | N/A | $0 | $0-100.0% | $6K-96.1% | $153K |
| Free Cash Flow | N/A | -$34.5M | N/A | N/A | -$26.3M+2.7% | -$27.0M+2.0% | -$27.6M-16.5% | -$23.6M |
| Investing Cash Flow | -$162.2M-1038.9% | $17.3M-49.5% | $34.2M+175.9% | -$45.1M+60.6% | -$114.4M-349.2% | $45.9M+1041.4% | -$4.9M+75.8% | -$20.1M |
| Financing Cash Flow | $213.6M+520758.5% | $41K+101.6% | -$2.5M-1234.2% | $222K-99.9% | $244.3M+265443.5% | $92K-99.4% | $15.6M+76.9% | $8.8M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
OLMA Financial Ratios
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | -13.7%-1.1pp | -12.7%-4.8pp | -7.9% | N/A | -17.4%-4.0pp | -13.4%-0.3pp | -13.1% |
| Return on Assets | N/A | -12.0%-0.5pp | -11.5%-4.0pp | -7.4% | N/A | -15.0%-3.1pp | -11.9%-0.2pp | -11.7% |
| Current Ratio | 9.95+1.9 | 8.03-3.1 | 11.09-4.1 | 15.22+4.7 | 10.50+3.4 | 7.10-2.0 | 9.13-0.5 | 9.61 |
| Debt-to-Equity | 0.11-0.0 | 0.15+0.0 | 0.11+0.0 | 0.07-0.0 | 0.10-0.1 | 0.16+0.0 | 0.120.0 | 0.12 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Olema Pharmaceuticals, Inc. profitable?
No, Olema Pharmaceuticals, Inc. (OLMA) reported a net income of -$162.5M in fiscal year 2025.
What is Olema Pharmaceuticals, Inc.'s EBITDA?
Olema Pharmaceuticals, Inc. (OLMA) had EBITDA of -$178.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Olema Pharmaceuticals, Inc.'s return on equity (ROE)?
Olema Pharmaceuticals, Inc. (OLMA) has a return on equity of -34.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Olema Pharmaceuticals, Inc.'s operating cash flow?
Olema Pharmaceuticals, Inc. (OLMA) generated -$146.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Olema Pharmaceuticals, Inc.'s total assets?
Olema Pharmaceuticals, Inc. (OLMA) had $533.4M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Olema Pharmaceuticals, Inc. spend on research and development?
Olema Pharmaceuticals, Inc. (OLMA) invested $157.7M in research and development during fiscal year 2025.
What is Olema Pharmaceuticals, Inc.'s current ratio?
Olema Pharmaceuticals, Inc. (OLMA) had a current ratio of 9.95 as of fiscal year 2025, which is generally considered healthy.
What is Olema Pharmaceuticals, Inc.'s debt-to-equity ratio?
Olema Pharmaceuticals, Inc. (OLMA) had a debt-to-equity ratio of 0.11 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Olema Pharmaceuticals, Inc.'s return on assets (ROA)?
Olema Pharmaceuticals, Inc. (OLMA) had a return on assets of -30.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Olema Pharmaceuticals, Inc.'s cash runway?
Based on fiscal year 2025 data, Olema Pharmaceuticals, Inc. (OLMA) had $48.3M in cash against an annual operating cash burn of $146.7M. This gives an estimated cash runway of approximately 4 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Olema Pharmaceuticals, Inc.'s Piotroski F-Score?
Olema Pharmaceuticals, Inc. (OLMA) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Olema Pharmaceuticals, Inc.'s earnings high quality?
Olema Pharmaceuticals, Inc. (OLMA) has an earnings quality ratio of 0.90x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.